{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004182","form_type":"8-K","ticker":null,"cik":"0001496671","company_name":"Calithera Biosciences, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.255756+00:00","generated_at":"2026-06-20T17:44:20.319073+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Calithera Biosciences board approves complete liquidation; common stockholders expected to receive no distributions","bullets":["Board unanimously approved dissolution and liquidation, subject to stockholder approval; special meeting in Q1 2023.","Reduction-in-force of substantially all employees; estimated $8M in severance and related charges.","CEO Susan Molineaux, CFO Stephanie Wong, and SVP Eric Sjogren to depart; CFO receives $100K retention bonus for wind-down.","All clinical programs discontinued; Company does not expect any liquidating distributions to common stockholders due to Series A preferred liquidation preference.","Plan to delist from Nasdaq, file certificate of dissolution upon approval, and satisfy remaining liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004182","json":"https://secwatch.observer/filing/0001193125-23-004182.json","markdown":"https://secwatch.observer/filing/0001193125-23-004182.md","text":"https://secwatch.observer/filing/0001193125-23-004182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/d406710d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:44:20.319073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"335ba2206b","claim":"Stephanie Wong departed as Chief Financial Officer at Calithera Biosciences, Inc..","evidence_excerpt":"Susan M. Molineaux, Ph.D., our President and Chief Executive Officer, and Stephanie Wong, our Chief Financial Officer, will also be leaving Calithera Biosciences as of future date to be determined","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will also be leaving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"91c77daa31","claim":"Eric Sjogren departed as Senior Vice President, Drug Discovery at Calithera Biosciences, Inc..","evidence_excerpt":"Eric Sjogren, Ph.D. our Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will be leaving"},{"label":"Role","value":"Senior Vice President, Drug Discovery"}],"fact_type":"executive_change"},{"claim_id":"9bbe04e03e","claim":"Susan M. Molineaux departed as President and Chief Executive Officer at Calithera Biosciences, Inc..","evidence_excerpt":"Susan M. Molineaux, Ph.D., our President and Chief Executive Officer, and Stephanie Wong, our Chief Financial Officer, will also be leaving Calithera Biosciences as of future date to be determined","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will also be leaving"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"72e1679edc560aa72ca1672b61e983fc86317274","claim":"Calithera Biosciences, Inc. announced a restructuring with charges of approximately $8 million affecting Calithera Biosciences, Inc. (complete dissolution) (reduction-in-force of substantially all our employees, including our executive officers).","evidence_excerpt":"We estimate that we will incur charges of approximately $8 million in connection with the reduction-in-force, primarily consisting of severance payments, notice pay (where applicable), employee benefits contributions and related costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $8 million"},{"label":"Affected area","value":"Calithera Biosciences, Inc. (complete dissolution)"},{"label":"Headcount","value":"reduction-in-force of substantially all our employees, including our executive officers"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}